Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 22, 2025Clinical and Experimental MedicineOpen Access

Efficacy and safety of doxycycline for severe Mycoplasma pneumoniae pneumonia in pediatric patients

View Full Paper
Ask AI
Bookmark
Share

Authors

QZQian ZhaoXSXu SangDGDing Gao

Discussion

Loading...

Member takes

Overview

Clinical analysis shows doxycycline improves pneumonia outcomes in children, indicating its efficacy and safety over macrolides.

Key Points

  • Doxycycline treatment led to shorter cough relief time (5.4 days) compared to macrolides (7.2 days), indicating better efficacy.
  • The treatment efficacy rate for doxycycline was 88.6%, while that for macrolides was 75.0%, showing a significant difference.
  • No notable differences were found in fever resolution time or hospitalization duration between the treatment groups.
  • Safety analysis indicated similar adverse event rates, primarily mild, emphasizing doxycycline's safety in pediatric use.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cd81chttps://doi.org/10.1007/s10238-025-01793-x
View Full Paper
Ask AI
Bookmark
Share